Hendrik Karel VAN Halteren1, Gerard Vreugdenhil2. 1. Department of Medical Oncology, ADRZ Medical Center, Goes, The Netherlands h.vanhalteren@adrz.nl. 2. Department of Medical Oncology, Maxima Medical Center, Veldhoven, The Netherlands.
Abstract
BACKGROUND/AIM: Enzalutamide is prescribed for advanced prostatic cancer patients, regardless of physical comorbidity. We hypothesized that comorbidity negatively affects survival regardless of age, performance status and prostate-specific antigen (PSA) response. PATIENTS AND METHODS: All patients (n=106) treated at the ADRZ Medical Center with enzalutamide in the period 2015-2018 and who had undergone at least one PSA response evaluation were included in a multivariate analysis to test which variables independently affected Time to PSA progression (TPSAP) and/or overall survival (OS). RESULTS: A poorer performance status appeared to relate to a two times increased risk of dying (HR=2.032, 95%CI=1.078-3.830). An older age did not appear to influence OS, whereas an ACCI of more than 9 points appeared to relate to a more than three times increased risk of dying (HR=3.538, 95%CI=1.466-8.538). CONCLUSION: Survival appeared to be strongly affected by comorbidity, irrespective of age and performance status in patients treated with enzalutamide. Copyright
BACKGROUND/AIM: Enzalutamide is prescribed for advanced prostatic cancerpatients, regardless of physical comorbidity. We hypothesized that comorbidity negatively affects survival regardless of age, performance status and prostate-specific antigen (PSA) response. PATIENTS AND METHODS: All patients (n=106) treated at the ADRZ Medical Center with enzalutamide in the period 2015-2018 and who had undergone at least one PSA response evaluation were included in a multivariate analysis to test which variables independently affected Time to PSA progression (TPSAP) and/or overall survival (OS). RESULTS: A poorer performance status appeared to relate to a two times increased risk of dying (HR=2.032, 95%CI=1.078-3.830). An older age did not appear to influence OS, whereas an ACCI of more than 9 points appeared to relate to a more than three times increased risk of dying (HR=3.538, 95%CI=1.466-8.538). CONCLUSION: Survival appeared to be strongly affected by comorbidity, irrespective of age and performance status in patients treated with enzalutamide. Copyright
Authors: Francesco Perri; Anna Crispo; Franco Ionna; Paolo Muto; Francesco Caponigro; Francesco Longo; Concetta Montagnese; Pierluigi Franco; Ettore Pavone; Corrado Aversa; Agostino Guida; Sabrina Bimonte; Alessandro Ottaiano; Massimiliano Di Marzo; Giuseppe Porciello; Alfonso Amore; Egidio Celentano; Giuseppina Della Vittoria Scarpati; Marco Cascella Journal: Exp Ther Med Date: 2021-09-16 Impact factor: 2.751